Phentolamine
- Generic Name
- Phentolamine
- Brand Names
- Oraverse
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O
- CAS Number
- 50-60-2
- Unique Ingredient Identifier
- Z468598HBV
- Background
Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine. It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis. Phentolamine is administered intravenously, intramuscularly, submucosally, and topically.
- Indication
1.用于预防和治疗嗜铬细胞瘤所致的高血压发作，包括手术切除时出现的阵发性高血压，也可根据血压对本品的反应用于协助诊断嗜铬细胞瘤；
2.治疗左心衰竭；
3.治疗去甲肾上腺素、去氧肾上腺素、间羟胺等静脉给药外溢，用于防止皮肤坏死；
4.临床还用于治疗男性勃起功能障碍（ED）。最新研究表明，本品与罂粟碱、前列地尔三联用药，可降低引起平滑肌收缩的交感神经张力，使阴茎动脉平滑肌松弛，增加阴茎动脉血流，有利勃起。
- Associated Conditions
- Mydriasis, Necrosis caused by norepinephrine extravasation, Pheochromocytoma, Sloughing Skin, Soft Tissue Anesthesia (Numbness), Hypertensive episodes
Sex Differences in Sympathetic Vascular Reactivity at High Altitude
- Conditions
- VasodilationVasoconstriction
- Interventions
- Other: Isometric Handgrip and Post-Exercise Circulatory OcclusionOther: Rhythmic HandgripOther: Cold Pressor Test
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 17
- Registration Number
- NCT05525416
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇦University of British Columbia - Okanagan, Kelowna, British Columbia, Canada
Oraverse Versus Laser
- Conditions
- Reversal of Local Anesthesia in Children
- Interventions
- Device: diode laser
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- sara nabil
- Target Recruit Count
- 40
- Registration Number
- NCT05473858
- Locations
- 🇪🇬
Dr.sara nabil, Cairo, Egypt
Effectiveness of Phentolamine Mesylate as a Reversing Agent for Local Anesthesia in Children
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 80
- Registration Number
- NCT05448807
Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
- Conditions
- MydriasisDilation
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT05223478
- Locations
- 🇺🇸
Clinical Site 2, Athens, Ohio, United States
🇺🇸Clinical Site 1, Longwood, Florida, United States
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
- Conditions
- ObesityVasodilationHealthy
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 72
- Registration Number
- NCT05219799
- Locations
- 🇺🇸
University of Missouri, Columbia, Missouri, United States
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
- Conditions
- MydriasisDilation
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 368
- Registration Number
- NCT05134974
- Locations
- 🇺🇸
Clinical Site 5, Pittsburg, Kansas, United States
🇺🇸Clinical Site 10, Newport Beach, California, United States
🇺🇸Clinical Site 9, Delray Beach, Florida, United States
Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia
- Conditions
- Presbyopia
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT04675151
- Locations
- 🇺🇸
Clinical Site 18, Saint Louis, Missouri, United States
🇺🇸Clinical Site 12, Laguna Hills, California, United States
🇺🇸Clinical Site 3, Pittsburg, Kansas, United States
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
- Conditions
- Dim Light Vision Disturbances
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT04638660
- Locations
- 🇺🇸
Clinical Site 13, Pittsburg, Kansas, United States
🇺🇸Clinical Site 1, Petaluma, California, United States
🇺🇸Clinical Site 19, Ogden, Utah, United States
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis
- Conditions
- MydriasisDilation
- Interventions
- Other: Phentolamine Ophthalmic Solution Vehicle (Placebo)
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 185
- Registration Number
- NCT04620213
- Locations
- 🇺🇸
Clinical Site 7, Pittsburg, Kansas, United States
🇺🇸Clinical Site 3, Shawnee Mission, Kansas, United States
🇺🇸Clinical Site 11, Newport Beach, California, United States
Sex Disparities in Hypoxic Sympatholysis and Impact of Obesity
- Conditions
- HealthyVasoconstrictionVasodilationObesity
- Interventions
- Other: Hypoxia Exposure
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 104
- Registration Number
- NCT04436731
- Locations
- 🇺🇸
University of Missouri-Columbia, Columbia, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.